Transplantation of RPE in age-related macular degeneration: observations in disciform lesions and dry RPE atrophy.
A study was carried out to investigate whether human RPE allografts are tolerated or rejected in the subretinal space and to determine the feasibility of RPE transplantation in subjects with age-related macular degeneration (AMD).


METHODS
Patches of human fetal RPE (13-20 weeks of gestational age) were transplanted into the subretinal space of five patients after surgical removal of subfoveal fibrovascular membranes, and to four subjects with dry geographic atrophy. Suspensions of RPE cells were transplanted to four other patients with nonexudative AMD. Results were evaluated with clinical ophthalmological examination, SLO microperimetry and fluorescein angiography over 8-20 months.


RESULTS
In disciform lesions, RPE transplants developed macular edema and fluorescein leakage concomitant with gradual reduction of visual acuity, implying host-graft rejection, over 1-6 months. In geographic atrophy, three of four transplants showed little change in shape and size after 12 months (one transplant was slowly rejected). In non-exudative AMD, RPE suspension transplants showed no evidence of rejection and were associated with the disappearance of drusen; visual acuity remained stable and SLO microperimetry confirmed retinal function over the transplanted area.


CONCLUSIONS
Human RPE allografts are not invariably rejected in the subretinal space without immunosuppression. The rejection rate is lower in nonexudative than in neovascular AMD. An intact blood-retinal barrier is likely to protect against rejection. It is technically feasible to transplant human RPE into the submacular space without adversely affecting visual function in nonexudative AMD over relatively long periods of time.
Algvere
P V
PV
Department of Ophthalmology, Karolinska Institute, St. Erik's Eye Hospital, Stockholm, Sweden.
Berglin
L
L
Gouras
P
P
Sheng
Y
Y
Kopp
E D
ED
D000375:Aging / Q000502:physiology*; D001284:Atrophy; D001834:Body Water / Q000378:metabolism*; D017690:Cell Transplantation; D005240:Feasibility Studies; D016332:Fetal Tissue Transplantation; D005333:Fetus / Q000166:cytology; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008268:Macular Degeneration / Q000601:surgery*; D010857:Pigment Epithelium of Eye / Q000196:embryology* / Q000378:metabolism / Q000473:pathology*; D011184:Postoperative Period; D014792:Visual Acuity